Price to book forward of CareDx, Inc. – NASDAQ:CDNA
This article displays the "Price to book forward" financial metric for CareDx, Inc. (NASDAQ: CDNA) on the TradingView platform. It indicates that the market was closed at the time of viewing, with no trades. The content primarily shows the navigation and footer elements of the TradingView website, with the core financial data point presented as "Period Value Change Change %".
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar
Zacks.com has identified five top-ranked, high-efficiency stocks expected to deliver strong returns: CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals, and Caterpillar. These companies were selected based on key efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, which indicate strong resource management and profitability potential. Each company has also demonstrated significant average four-quarter earnings surprises.
Price to book forward of CareDx, Inc. – DUS:1K9
This page provides financial data for CareDx, Inc. (DUS:1K9) on the Dusseldorf Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is currently closed with no trades. It also details the various data providers and copyright information for the financial data presented.
CareDx (NASDAQ: CDNA) insider lines up $423K stock sale
CareDx (NASDAQ: CDNA) insider Peter Maag has filed a Form 144 notice to sell 9,122 shares of common stock, valued at approximately $423,091. This planned sale involves restricted stock grants from June 2023 to July 2024 and follows previous sales by Maag in August 2026, totaling over 149,000 shares. The filing indicates 51,734,223 shares of CareDx common stock are currently outstanding.
CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales
Peter Maag, an insider at CareDx (CDNA), has filed to sell 7,000 common shares valued at $317,112.60 through Morgan Stanley Smith Barney LLC. This proposed sale follows several other significant common stock sales by Maag over the past three months, including blocks of 75,653, 46,963, and 27,332 shares. The company has 51,734,223 shares outstanding, and the stock is traded on NASDAQ.
Baron group trims CareDx (CDNA) stake to 3.75% in latest 13G/A
Baron Capital Group, including its affiliates BAMCO, Inc. and Baron Capital Management, Inc., and Ronald Baron, have filed an amended Schedule 13G for CareDx, Inc. (CDNA), reporting a beneficial ownership of 1,937,326 shares, which represents 3.75% of the company's common stock. This filing indicates that their ownership is now 5% or less, with shared voting and dispositive power over these shares, and clarifies that advisory clients hold the economic rights to dividends and sale proceeds. The previous stake was not explicitly stated, but the current filing signifies a reduction below the 5% threshold.
Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?
CareDx, Inc. reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue outlook to US$490–500 million, while also managing its balance sheet through a buyback and ESOP filing. The article examines how this updated guidance impacts the investment narrative, particularly concerning growth, margins, and the ongoing risks associated with Medicare reimbursement policies. It also highlights differing analyst perspectives and encourages investors to conduct their own research, offering a comprehensive report for CareDx.
Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?
CareDx (CDNA) reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue guidance to US$490–500 million, while also completing a share buyback and filing for an ESOP-related share registration. Despite this positive financial performance and a Medicare LCD confirming coverage for key tests, the company's investment narrative remains heavily influenced by potential future changes in Medicare policies and competitive pressures. Analyst opinions on CareDx's future earnings and valuation vary, highlighting the complexity of its long-term outlook.
CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares
CareDx, Inc. insider Peter Maag has filed a notice to sell 7,000 shares of common stock, valued at $328,237.70, through Morgan Stanley Smith Barney LLC. These shares originated from restricted stock awards in late 2023 and early 2024. The filing also disclosed recent sales by Maag between August 4 and August 11, 2026, totaling over 120,000 shares for approximately $5.7 million.
Baron Discovery Fund Gains from Strategic Accumulation of CareDx (CDNA)
The Baron Discovery Fund increased its position in CareDx (CDNA) after shares declined in Q3 2025 due to a draft local coverage decision by CMS that threatened reimbursement for its diagnostic tests. The fund believed the stock was undervalued at $11-12, representing a worst-case scenario. CareDx's shares have since rebounded, reflecting better understanding of the CMS process and strong Q1 2026 results, including revenue growth and strategic acquisitions.
CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales
CareDx, Inc. (CDNA) insider Peter Maag has filed a Form 144 notice to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, valued at $333,851 as of August 11, 2026. This proposed sale follows several large prior sales by Maag in the past three months, including 75,653 shares on August 4, 2026, for $3,576,851.19, and additional sales on August 5, 7, and 10, 2026. The filing indicates a consistent pattern of insider share disposals.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 7, 2026
CareDx, Inc. announced inducement grants of restricted stock units (RSUs) to 35 new employees as a material incentive for their employment. A total of 97,090 shares of common stock were awarded, with most RSUs vesting over four years and one employee's RSUs vesting 100% after one year, subject to continued service. These awards were made under the company's 2025 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
This Insider Has Just Sold Shares In CareDx
CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of stock, reducing his holding by 24%. While significant, the sale occurred at current prices, making it less concerning than a sale at a lower price. Despite the insider selling, CareDx maintains strong insider ownership at 4.6% and is a profitable, growing company, though some caution is advised due to past sales and identified warning signs.
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx, Inc. (NASDAQ:CDNA) recently reported strong earnings, leading to a share price increase. However, an analysis of the accrual ratio revealed that its free cash flow significantly lagged its statutory profit, partly due to unusual items boosting profit. The article suggests that while headline numbers look good, the underlying earnings power might not be as strong as a superficial glance at statutory profits would suggest.
This Insider Has Just Sold Shares In CareDx
CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of shares, reducing his total holding by 24%. While this is the largest insider sale in the past year, the shares were sold at a price close to the current market value. Despite no insider purchases in the last year, the company's profitability, growth, and high insider ownership (4.6%) temper concerns from the share sales.
State Street (CDNA holder) discloses 2.47M CareDx shares under shared control
State Street Corporation has reported a beneficial ownership of 2,468,858 shares of CareDx, Inc. common stock, which represents 4.8% of the class, according to a Schedule 13G SEC filing. All voting and dispositive authority for these shares is shared through affiliated investment adviser entities. The filing indicates that State Street holds less than 5% of CareDx's common stock, classifying it as a passive investment.
CareDx (CDNA): Neil Gagnon and Gagnon entities report 4.4% ownership stake
Neil Gagnon and his affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a collective ownership stake of 4.4% in CareDx, Inc. (CDNA) common stock through a SCHEDULE 13G/A SEC filing. Neil Gagnon individually beneficially owns 2,293,464 shares (4.4%), while Gagnon Securities LLC holds 1,629,867 shares (3.2%) and Gagnon Advisors, LLC holds 408,837 shares (0.8%). The filing details the sole and shared voting and dispositive powers over these shares, clarifying that beneficial ownership of client-held securities is disclaimed.
CareDx (NASDAQ: CDNA) insider Peter Maag plans 27,332-share stock sale after option exercise
CareDx, Inc. insider Peter Maag has filed to sell 27,332 shares of Common Stock, which are tied to a stock option exercise dated August 7, 2026. The sale will be executed on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The filing also discloses prior sales by Maag of 46,963 shares on August 5, 2026, valued at $2,178,945.34, and 75,653 shares on August 4, 2026, valued at $3,576,851.19.
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx's recent strong earnings report was met with a positive market response, but an analysis of its financial ratios reveals underlying issues. The company's high accrual ratio of 0.28 suggests its free cash flow significantly lagged its statutory profit, indicating that non-recurring unusual items heavily boosted reported earnings. This analysis suggests that CareDx's statutory profits may not accurately reflect its true underlying financial health.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. announced inducement grants of restricted stock units (RSUs) to 35 new employees as a material incentive for their employment. A total of 97,090 shares of common stock were awarded, with varying vesting schedules over four years or one year, subject to continued service. These awards were made under the company's 2025 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx's recent strong earnings report, while positive on the surface, may not fully reflect the company's underlying financial health. The analysis highlights a high accrual ratio of 0.28, indicating that free cash flow significantly lagged statutory profit, partly due to a US$109m boost from unusual items. This suggests that the statutory profit may not be a reliable guide to the company's true earning power.
Janus Henderson Group PLC Has $5.50 Million Stock Position in CareDx, Inc. $CDNA
Janus Henderson Group PLC has increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 10.1% to 316,519 shares, valued at approximately $5.5 million. This comes as CareDx reported stronger-than-expected quarterly earnings with $0.37 EPS and revenue of $131.95 million, a 52.2% year-over-year increase. Despite a "Hold" consensus rating and insider selling of over $3.77 million in shares, several analysts have upgraded the stock.
CareDx, Inc. (CDNA) insider sells 2,688 shares under trading plan
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack sold 2,688 shares of common stock on August 5, 2026, under a Rule 10b5-1 trading plan established in September 2025. The sales were executed in two tranches at weighted average prices of $46.1492 and $46.75 per share, respectively, totaling approximately $124,000. Following these transactions, Novack directly holds 106,075 shares of CareDx common stock.
Dimensional Fund Advisors LP Has $25.38 Million Stock Position in CareDx, Inc. $CDNA
Dimensional Fund Advisors LP significantly increased its stake in CareDx, Inc. by 11.6% in the first quarter, now holding 1.46 million shares valued at $25.38 million. This comes as CareDx reported stronger-than-expected quarterly earnings and revenue. Despite mixed analyst ratings and recent insider stock sales, several institutional investors have also boosted their positions in the precision diagnostics company.
CareDx, Inc. (CDNA) director sells 16,000 shares in planned trade
CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on August 4, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $46.9358 per share, ranging from $46.25 to $47.2250, leaving her with 42,943 shares. This transaction, categorized as a sale in the open market, highlights planned insider trading activity for CDNA.
CareDx, Inc. SEC Filing (Aug 5, 2026)
This article details a CareDx, Inc. (CDNA) SEC Filing on Form 144, dated August 5, 2026. The filing indicates a proposed sale of 20,000 shares of common stock by an individual who acquired them as compensation for past services in 2015, with an aggregate market value of $925,700. The transaction is set to occur on August 5, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ.
Planned 46,963-share sale reported by CDNA insider (CDNA)
A Form 144 notice for CareDx, Inc. (CDNA) indicates a proposed sale of up to 46,963 shares of common stock, valued at $2,178,945.34 as of August 5, 2026, through Morgan Stanley Smith Barney LLC. These shares originate from restricted stock grants and a stock option exercise. The filing also reports that Peter Maag previously sold 75,653 shares for over $3.5 million within the last three months.
CareDx, Inc. SEC Filing (Aug 5, 2026)
This article details an SEC Form 144 filing by CareDx, Inc. (CDNA) on August 5, 2026. The filing indicates a proposed sale of 2,688 shares of common stock with an aggregate market value of $126,577.92 by an individual, acquired through Restricted Stock Units on August 1, 2026. The sale is to be conducted via Morgan Stanley Smith Barney LLC on NASDAQ.
Price to sales forward of CareDx, Inc. – LS:A118WG
This article provides financial information for CareDx, Inc. (A118WG) from TradingView, focusing on its price to sales forward metric. It indicates that no trades were recorded and the market was closed. The content is primarily a data page with various links to other financial tools and community features offered by TradingView.
CareDx, Inc. SEC Filing (Aug 4, 2026)
This article reports on CareDx, Inc.'s SEC Form 144 filing from August 4, 2026. The filing indicates a proposed sale of securities, specifically 31,943 shares of common stock acquired through a stock option exercise on the same date, valued at over $1.5 million, to be sold on NASDAQ via Morgan Stanley Smith Barney LLC.
Why CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf
CareDx (CDNA) saw a 33.8% stock increase after reporting strong Q2 2026 results, including a significant rise in revenue and net income. The company also raised its full-year 2026 revenue outlook and filed an ESOP shelf registration, which has reframed its investment narrative amidst ongoing discussions about transplant surveillance testing reimbursement. Despite the positive outlook, investors are cautioned about potential policy changes regarding bundled payments and test frequency, which could impact future volumes and margins.
Why CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf
CareDx reported strong Q2 2026 results with significant revenue and net income increases, leading to a 33.8% stock surge. The company raised its full-year 2026 revenue outlook to US$490 million–US$500 million and filed an US$80.30 million shelf registration for an employee stock ownership plan. Despite this positive news, the investment narrative still faces risks related to potential policy changes in Medicare reimbursement and bundled payments.
CareDx climbs another 9% after guidance raise, sets new 52-week high (CDNA:NASDAQ)
CareDx (CDNA) shares rallied over 9%, extending a previous 15% surge, after the company raised its full-year revenue guidance and reported strong second-quarter results. The precision medicine diagnostics company, focused on transplant patients, reached a new 52-week high. Key drivers include testing services segment growth and positive updates on its portfolio transformation, though risks like high short interest and valuation concerns remain.
CareDx Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against CareDx Inc. (NASDAQ: CDNA) and reminds investors of the July 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that CareDx engaged in improper schemes to inflate testing services revenue, which led to government investigations and significant drops in stock price. Investors who suffered losses exceeding $100,000 between February 24, 2021, and May 5, 2022, are encouraged to contact the firm.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) has announced inducement grants of 15,822 restricted stock units (RSUs) to James McNally, their newly appointed Executive Advisor. These RSUs were granted under the Company's 2025 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of Mr. McNally's employment package, with vesting scheduled for January 2, 2027, and July 2, 2027, subject to continued service.
CareDx: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for CareDx. Unfortunately, the content of the article itself is missing, preventing a detailed summary of the financial performance or key highlights.
CareDx Announces Second Quarter 2026 Financial Results
CareDx, Inc. reported strong second-quarter 2026 financial results, with a 52% year-over-year revenue increase to $132 million and GAAP net income of $111 million. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and adjusted EBITDA guidance to $66 million to $78 million, following the divestiture of its Lab Products business and acquisition of Naveris. These results reflect growth in Testing Services and Patient and Digital Solutions, reinforcing CareDx's focus on precision medicine diagnostics for transplant, specialty oncology, and cell therapy.
Earnings Flash (CDNA) CareDx, Inc. Reports Q2 Revenue $131.9M, vs. FactSet Est of $113.8M
CareDx, Inc. (CDNA) reported Q2 revenue of $131.9 million, surpassing the FactSet estimate of $113.8 million. The company also announced adjusted EPS of $0.37 per share, significantly higher than the FactSet estimate of $0.23 per share. These financial results indicate a strong performance for the precision medicine diagnostics company.
CareDx: Q2 Earnings Snapshot
The article "CareDx: Q2 Earnings Snapshot" appears to be a placeholder or an incomplete news item. It only provides a title and no actual content regarding CareDx's Q2 earnings, preventing any meaningful summary.
CareDx, Inc. (CDNA) Q2 2026 Earnings
CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was driven by a 61% surge in Testing Services revenue and boosted cash reserves to $373.6 million following a strategic lab divestiture.
CareDx, Inc. 2Q 2026: Revenue $131.95M, EPS $2.07— 10-Q Summary
CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab products business. The company also increased investments in R&D and sales and marketing to support future growth and commercialization efforts.
CareDx Number of Employees 2026 | Employee Count & Headcount Data
CareDx, Inc. (CDNA) had approximately 805 total employees worldwide as of March 2026, marking a 14.9% growth from 700 employees in 2023. The company is actively hiring, with 92 active job postings in 2026, though this represents a 28.0% decline from 2025. CareDx's workforce is concentrated in the United States, and its largest departments are Finance and Operations, Engineering, and Sales and Marketing.
Kidney Transplant AlloSure dd-cfDNA Monitoring Market : Global Industry Analysis and Opportunity Assessment, 2036
The global Kidney Transplant AlloSure dd-cfDNA Monitoring Market is projected to grow from USD 592.6 million in 2026 to USD 1315.4 million by 2036, at a CAGR of 8.3%. This growth is driven by the increasing need for repeatable molecular evidence in kidney transplant programs to aid in graft surveillance and distinguish routine monitoring from cases requiring invasive evaluation. Key market segments include donor-derived cell-free DNA (dd-cfDNA) monitoring, acute rejection monitoring, and transplant centers as end-users, with significant growth expected in the USA, UK, Japan, and South Korea.
CDNA|CareDx Inc|Price:36.380|Chg%:-0.760
This article provides a detailed company profile for CareDx Inc (CDNA), a precision medicine solutions company specializing in healthcare solutions for transplant patients. It outlines their business scope, including various testing services and digital solutions, and provides key financial data, market performance metrics, and a list of company executives with their shareholdings. The report also addresses frequently asked questions about top shareholders, institutional holdings, and the primary source of revenue for CareDx Inc.
CareDx Inc (CDNA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend history and stock splits for CareDx Inc (CDNA). It notes that the company has not distributed any dividends over the past five years. The page also presents current stock pricing, market capitalization, and links to various financial analysis tools on the TradingKey platform.
CareDx Inc (CDNA) Institutional Confidence
CareDx Inc (CDNA) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.54%, despite an 11.87% decrease quarter-over-quarter. Ron Baron is the largest institutional shareholder, holding 2.61 million shares, which represents 6.51% of outstanding shares.
Is CareDx (CDNA) Fully Valued After Its Medicare Coverage Win?
CareDx (CDNA) is in focus after Medicare finalized coverage for its molecular transplant surveillance tests, leading to a significant recent surge in its stock price. While analysts and one valuation model view the stock as overvalued at $38.37 against a fair value of $27.80, another discounted cash flow model by Simply Wall St suggests it is significantly undervalued. The article highlights the conflicting narratives and encourages investors to review the data to form their own conclusions.
This company is letting a virus guide its new focus on cancer testing
CareDx Inc. is changing its strategic direction to focus on cancer testing, a move influenced by a virus. CEO John Hanna emphasizes the importance of being a market leader in their chosen fields. This new focus is highlighted by their significant $260 million acquisition of Naveris.
CareDx (CDNA) AGM 2026 Summary
This article summarizes CareDx's 2026 Annual General Meeting (AGM), which included the re-election of five directors, ratification of the auditor, advisory votes on executive compensation, and an amendment to the equity incentive plan. No shareholder proposals were received. The summary also highlights recent company events, including strong financial performance, strategic acquisitions, and pipeline expansion.
CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overva
CareDx Inc (CDNA) shares dropped 3.4% to $38.37, yet its GF Value™ indicates the stock is significantly overvalued by 79.8%. Despite a GF Score™ of 66/100 suggesting above-average long-term potential, its valuation rank is low (1/10) and insiders have sold $8.3 million worth of shares, signaling potential concerns. Investors are cautioned due to the substantial premium over its intrinsic value and historical P/E multiples being well above its 5-year median.
